- LXRP
recently added multiple highly respected experts to its scientific
advisory board
- The
company is readying for growth by ensuring executive continuity
- LXRP
continues to conduct research regarding oral nicotine
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has
bolstered its future growth prospects by adding four new members to its
scientific advisory board and renewing executive contracts with three-year
compensation deals for key officers, including CEO Chris Bunka and President
John Docherty. The agreements and new advisory board team members offer LXRP
and its shareholders seamless executive continuity (http://ibn.fm/oBuUZ).
New members of LXRP’s scientific advisory board
include (http://ibn.fm/KSdJ3):
- Dr.
Dwayne Godwin, dean of the graduate school and professor in the
Departments of Neurobiology and Anatomy at the Institute for Regenerative
Medicine at Wake Forest University;
- Dr.
Terry D. Blumenthal, professor of psychology and neuroscience at Wake Forest
University;
- Dr.
Matthew Fraser, an associate professor and director of basic science
research in the Department of Surgery, Division of Urology, at Duke
University Medical Center; and
- Dr.
Carla Lema Tome, an industry consultant and adjunct assistant professor of
neurobiology and anatomy at Wake Forest University School of Medicine.
“Lexaria Bioscience Corp. is very pleased to welcome these
accomplished experts to our Advisory Board,” Bunka stated in a news release.
“[They] can provide critical scientific guidance to Lexaria’s ongoing and
future R&D programs. Lexaria is building towards becoming one of the
world’s leaders in drug delivery technology, and our most recent advisors can
assist in achieving that goal.”
In addition, the new three-year executive agreements offer
both Bunka and Docherty compensation and bonuses based on meeting certain
performance criteria, as established by LXRP’s board.
Based in British Columbia, Canada, LXRP is a biotechnology
company and drug-delivery platform innovator. DehydraTECH is the company’s
proprietary absorption technology platform. LXRP has developed and out-licenses
its disruptive technology, which promotes healthier ingestion methods and lower
overall dosing. LXRP is conducting research for DehydraTECH’s potential applications
for oral nicotine absorption (http://ibn.fm/HGStA).
LXRP holds a patent for oral delivery of all cannabinoids.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
